Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Annals of hematology. - 100 (2021) , 1637–1640, ISSN: 1432-0584
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2021
- Urheber
- DOI
-
10.1007/s00277-021-04490-3
- URN
-
urn:nbn:de:bsz:25-freidok-1945356
- Rechteinformation
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
Entstanden
- 2021
Ähnliche Objekte (12)
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER)
15-year remission in refractory FLT3-mutated AML attained by sorafenib
15-year remission in refractory FLT3-mutated AML attained by sorafenib
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine
S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab
Response to daratumumab-retreatment in patients with multiple myeloma
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER)
15-year remission in refractory FLT3-mutated AML attained by sorafenib
15-year remission in refractory FLT3-mutated AML attained by sorafenib
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine
S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab
Response to daratumumab-retreatment in patients with multiple myeloma
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER)
15-year remission in refractory FLT3-mutated AML attained by sorafenib
15-year remission in refractory FLT3-mutated AML attained by sorafenib
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine
S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab
Response to daratumumab-retreatment in patients with multiple myeloma